Navigation Links
PAREXEL Expands Clinical Trial Supply And Logistics Services Through Opening Of New European Coordination Hub and Distribution Center
Date:11/11/2014

BOSTON, Nov. 11, 2014 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the opening of its new European Coordination Hub and Distribution Center in Berlin-Schonefeld, Germany.  The facility expands the Company's capacity to provide comprehensive clinical trial supply and logistics services to support clients' local, regional and global trial requirements.  These capabilities include synchronized coordination of clinical trial supplies, ancillary supplies and central laboratory services. 

"To safely and efficiently conduct clinical trials, our customers need highly specialized clinical supply and logistics services for studies that can span dozens of countries and hundreds of sites around the world," said Mark A. Goldberg, President and Chief Operating Officer, PAREXEL. "Our new European distribution center reflects a commitment to simplify the important end-to-end supply-management aspect of the drug-development journey."

The facility features more than 65,000 cubic meters of storage space.  It offers lab-kit assembly and provides storage and distribution of ancillary materials.

"Through this center, we can customize sourcing and distribution strategies for customers in ways that are efficient, robust and compliant with local regulations," said Thomas Senderovitz, Senior Vice President, Clinical Research Services, PAREXEL.  "In addition, from this central location, we can provide responsive, timely delivery services to all EU destinations."

The new European Coordination Hub and Distribution Center will be licensed to store Investigational Medicinal Products (IMPs) and Non-Investigational Medicinal Products (N-IMPs).  It will also offer secondary packaging, re-labeling, and compliance with Good Distribution Practice (GDP) of medical devices and ambient, refrigerated and frozen medicinal products, including controlled substances.  On-site Qualified Person (QP), Quality Control (QC) and production personnel will manage regulatory-compliance requirements.  They will also streamline product import, receipt, storage, packaging and labeling, release, shipment, return and destruction timelines.

PAREXEL also is opening new full-service clinical trial supply depots in Buenos Aires, Argentina, and Sao Paulo, Brazil.  The facilities are part of PAREXEL's growing global system of more than 50 owned or in-network depots and three regional distribution centers.  They are designed to help ensure a seamless flow of materials and timely clinical site supply delivery around the world.

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 81 locations in 51 countries around the world, and has approximately 15,980 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation or its affiliates.

This release contains "forward-looking" statements regarding future results and events.  For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisitions of LIQUENT, Inc. and HERON, Inc., or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.  Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2014 as filed with the SEC on August 20, 2014, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

Contacts:
Diana Martin, Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com

Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com

Photo - http://photos.prnewswire.com/prnh/20141107/157408


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
2. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
3. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
4. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening
5. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
6. PAREXEL International To Present At NASDAQ OMX Investor Conference
7. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2012 Earnings Release and Conference Call
8. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
9. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
10. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
11. PAREXEL International to Present at Robert Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2018)... ... 13, 2018 , ... As the life science industry continues ... well as top talent, have the ability to remain agile and keep pace ... years of working hand-in-hand with some of the country’s top pharmaceutical, biotech, and ...
(Date:12/13/2018)... ... December 13, 2018 , ... Women’s Excellence is pleased to ... the GE Voluson E6 ultrasound to provide superior imaging, resolution, and 3D/4D imaging. ... the forefront of innovation and technological offerings to our patients. Equipment continues ...
(Date:12/13/2018)... ... December 13, 2018 , ... Sponsorship and exhibitor opportunities ... 4, 2019, at the Hyatt Regency in Chicago. , The event includes ... attendees. In attendance will be the top C-suite executives from hospitals and health ...
Breaking Medicine Technology:
(Date:12/14/2018)... ... ... The Parenteral Drug Association (PDA) today announced the results of its Board ... 2018, PDA’s 10,500 members had an opportunity to participate in the election of new ... Board of Directors for three-year terms starting Jan. 1, 2019: , ...
(Date:12/13/2018)... Texas (PRWEB) , ... December 13, 2018 , ... ... that improves patient visibility, operational efficiency and financial outcomes, introduced new enhancements to ... on quality care and financial leadership, rather than technology and screen time. ...
(Date:12/13/2018)... WASHINGTON (PRWEB) , ... December 13, 2018 , ... ... Brad Swelstad, M.D., to the practice’s Virginia medical team, seeing patients ... Woodbridge, VA with a full range of state-of-the-art diagnostic and treatment options for ...
(Date:12/13/2018)... ... December 13, 2018 , ... FOR IMMEDIATE RELEASE , Fellow ... commitment to providing more jobs in America, Fellow Health Partners introduces Knowledge College™ ... York based medical business solutions company, today announced the launch of Knowledge College ...
(Date:12/13/2018)... ... December 13, 2018 , ... Individuals who are interested in entering ... a full-ride scholarship offered by Dr. Kami Hoss of Howard Healthcare Academy. , The ... scholarship would enable a student to become a registered dental assistant for free in ...
Breaking Medicine News(10 mins):